Patrick Mitchell

Pharmacodynamic effects and pharmacokinetics of a new HMG‐CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers

Paul Martin, Patrick Mitchell, Dennis W. Schneck · British Journal of Clinical Pharmacology · 2002 · 150 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Ian W. Flinn, Nancy L. Bartlett, Kristie A. Blum et al. · European Journal of Cancer · 2015 · 72 citations

Medicine, Hematology, Oncology +14

Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers

Renli Teng, Patrick Mitchell, Kathleen Butler · European Journal of Clinical Pharmacology · 2012 · 64 citations

Pharmacy, Pharmacokinetics, Pharmacology +10

A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results

Ezra E.W. Cohen, Kevin J. Harrington, David S. Hong et al. · Annals of Oncology · 2018 · 63 citations · Full text

Medicine, Oncology, Pharmacology +17

Effect of Rosuvastatin on Warfarin Pharmacodynamics and Pharmacokinetics

Steven G. Simonson, Paul Martin, Patrick Mitchell et al. · The Journal of Clinical Pharmacology · 2005 · 51 citations

Medicine, Pharmacokinetics, Pharmacology +11